Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recce Reports Positive Preclinical Data Against WHO Priority Pathogen Acinetobacter
Details : RECCE 327 (R327) is a novel topical Bacterial ATP production inhibitor which is under phase 1/2 clinical development for the treatment of Acinetobacter baumannii Infections.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 07, 2024
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recce Pharmaceuticals Reports Positive Data Of RECCE® 327 in Lung Infection Study
Details : R327 (RECCE-327) is a fast-acting, broad-spectrum anti-infective effective against Gram-positive and Gram-negative bacteria, including their resistant forms. Under development for lung infections.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 13, 2024
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Murdoch Children’s Research Institute
Deal Size : Undisclosed
Deal Type : Partnership
Recce Pharmaceuticals Continues Partnership with Murdoch Children's Research Institute
Details : The collaboration aims to focus on the clinical advancement of RECCE 327 (R327). Currently it is being evaluated in the clinical trial studies for Urinary tract infections including urosepsis.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Undisclosed
February 29, 2024
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Murdoch Children’s Research Institute
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 Against Gonorrhea
Details : R327 (RECCE-327) is a fast-acting, broad-spectrum anti-infective effective against Gram-positive and Gram-negative bacteria, including their resistant forms. It is under preclinical development for the treatment of Gonorrhea.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 18, 2023
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R529
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recce Pharmaceuticals to be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives
Details : Recce® 327 an anti-infective compound which can be administered for intravenous, topical, nasal, oral and inhaled use. RECCE® 327’s universal mechanism of action has a patented ability to continuously kill bacteria without tendency for the emergence ...
Product Name : R529
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2023
Lead Product(s) : R529
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recce Pharmaceuticals Announces Preclinical SARS-CoV-2 Study Update
Details : Treatment with R327 (RECCE® 327) has shown to significantly reduce SARS-CoV-2 levels in a dose-dependent manner in throat swab samples collected from animals. This study provides proof-of-concept that IN treatment with R327 has the potential to reduce S...
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 18, 2022
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bovine Colostrum
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Immuron Update on IMM-124E SARS-CoV-2 Research
Details : In consideration of research findings, the rapid evolution of the virus and changing treatment landscape presents significant challenges to conduct a clinical trial for SARS-CoV-2 with IMM-124E (travelan).
Product Name : Travelan
Product Type : Antibody
Upfront Cash : Inapplicable
August 19, 2022
Lead Product(s) : Bovine Colostrum
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Macquarie University
Deal Size : Undisclosed
Deal Type : Collaboration
Government Grant to Apply NanoCelle® to an RNA Nasal Vaccine
Details : This Government Grant & Academic collaboration solidify Medlab’s transition to a true Biotech company. The NanoCelle® non-invasive nasal delivered vaccine is considered a “first in class” medicine delivery system.
Product Name : NanoCelle
Product Type : Vaccine
Upfront Cash : Undisclosed
January 14, 2022
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Macquarie University
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Of the 36 candidates in clinical development, R327 is the only synthetic polymer drug candidate and the only clinical stage antibiotic for the indication of sepsis – globally.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 26, 2021
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recce Anti-Viral Patent Granted in USA for RECCE® Anti-Infectives
Details : Patented lead candidate RECCE® 327 as an intravenous therapy, is being developed for treatment of serious and potentially life-threatening infections including sepsis due to Gram-positive and Gramnegative bacteria including their superbug forms.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 22, 2021
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable